We started the year with a large screening study conducted with more than 65,000 people. The results from this study were so successful that we got a lot of international attention when we presented them as late breaking science presentations at both the European and the United States cardiology conferences.
We had the successful extension of our CE quality labels as a medical device. We had to, but we also care a lot about the quality we deliver to our customers.
In 2019 we also started with reaching out to consumers directly. A super important milestone for FibriCheck, certainly if you look at the potentential impact this approach can have for people in countries where access towards medical professionals is limited or challenging.
On top of that, we extended our product portfolio and launched our collaboration with Fitbit in September, so today people cannot only check their heart rhythm on their smartphones but als on their Fitbit smartwatches.
In 2019 we reached over 165,000 people and detected over 16,000 arrhythmias.
The focus for 2020 is to get FibriCheck to even more people, and here we do believe we are ready to build some very strong collaborations with insurance companies. It is clear that due to the aging society, we need to focus on prevention, to keep healthcare costs affordable for everyone.
We aim to obtain regulatory approvals in new regions, such as the United States of America and Australia, to fully unlock the potential of FibriCheck in these regions. And we will keep demonstrating compliance to all requirements of being a medical device.
Another very big milestone we’re aiming for in 2020 is the release of our updated smartwatch application. This upgrade will enable people to monitor their heart rhythm continiously while they are sleeping. This will make it easier to find paroxysmal episodes of atrial fibrillation, that are not always felt by patients. This update will be a major milestone towards our mission, which is preventing atrial fibrillation related strokes.